생화학분자생물학회입니다.
A new horizon of precision medicine: combination of the microbiome and extracellular vesicles
작성자
Yoon-Keun Kim작성일자
2022-07-19조회수
97Yoon-Keun Kim( ykkim@mdhc.kr ) | ||
2014. 10-Present | CEO, MD Healthcare Inc | |
2014-2015 | Director, Ewha Institute of Convergence Medicine, Ewha Womans University Medical Center | |
2006-2014 | Professor, Department of Life Science, Pohang University of Science and Technology (POSTECH) | |
1999-2006 | Professor, Department of Internal Medicine, Seoul National University College of Medicine | |
1995-1997 | Fellow, Division of Allergy and Clinical Immunology in Internal Medicine Department, Seoul National University Hospital | |
1993-1997 | MS & PhD, Seoul National University College of Medicine | |
1991-1995 | Resident, Department of Internal Medicine, Seoul National University Hospital |
A new horizon of precision medicine: combination of the microbiome and extracellular vesicles
Over several decades, the disease pattern of intractable disease has changed from acute infection to chronic disease accompanied by immune and metabolic dysfunction. In addition, scientific evidence has shown that humans are holobionts; of the DNA in humans, 1% is derived from the human genome, and 99% is derived from microbial genomes (the microbiome). Extracellular vesicles (EVs) are lipid bilayer-delimited nanoparticles and key messengers in cell-to-cell communication. Many publications indicate that microbial EVs are both positively and negatively involved in the pathogenesis of various intractable diseases, including inflammatory diseases, metabolic disorders, and cancers. Microbial EVs in feces, blood, and urine show significant differences in their profiles between patients with a particular disease and healthy subjects, demonstrating the potential of microbial EVs as biomarkers for disease diagnosis, especially for assessing disease risk. Furthermore, microbial EV therapy offers a variety of advantages over live biotherapeutics and human cell EV (or exosome) therapy for the treatment of intractable diseases. In summary, microbial EVs are a new tool in medicine, and microbial EV technology might provide us with innovative diagnostic and therapeutic solutions in precision medicine.
Experimental & Molecular Medicine; https://doi.org/10.1038/s12276-022-00748-6